SCHEMBL12073000

SCHEMBL12073000

CCOC(=O)Nc1c(Oc2ccc(N)c(Cl)c2Cl)ccnc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.40
AXL P30530 3/20 0.38
RET P07949 2/20 0.38
KIT P10721 2/20 0.38
PDGFRA P16234 2/20 0.38
KDR P35968 2/20 0.38
FLT3 P36888 2/20 0.38
PLK4 O00444 1/20 0.38
ABL1 P00519 1/20 0.38
NTRK1 P04629 1/20 0.38
LCK P06239 1/20 0.38
PRKACA P17612 1/20 0.38
ABL2 P42684 1/20 0.38
FRK P42685 1/20 0.38
MST1R Q04912 1/20 0.38
TYRO3 Q06418 1/20 0.38
DDR1 Q08345 1/20 0.38
PDE4D Q08499 1/20 0.38
MAP4K2 Q12851 1/20 0.38
MERTK Q12866 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12435854 0.83 KDM4E (0.47) METKDRKDM4EGLAPOLB
SCHEMBL12847420 0.81 KDM4E (0.42) PDE4DKDM4EGLAPOLBNLRP3
SCHEMBL15034567 0.80 MET (0.38) METAXLRETKITPDGFRA
SCHEMBL4469381 0.79 RAB9A (0.44) KDRKDM4EGLAPOLBMAPKAPK2
SCHEMBL2315882 0.79 KCNQ3 (0.39) METAXLKITPDGFRAKDR
SCHEMBL24802656 0.79 MET (0.45) METAXLRETKITPDGFRA
SCHEMBL30785618 0.79 MET (0.45) METAXLRETKITPDGFRA
SCHEMBL30146868 0.79 MET (0.45) METAXLRETKITPDGFRA
SCHEMBL12071514 0.77 MET (0.36) METAXLRETKITPDGFRA
SCHEMBL27171642 0.77 MET (0.54) METAXLRETKITPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10358445-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2019-07-23 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
EP-2582700-B1 RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS RESPIVERT LTD (GB) 2016-11-02 EP disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
WO-2011158044-A2 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2011-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN TSLP, CCL11, RORB MET 4275/4885AXL 3775/4885RET 2195/4885
US-10358445-B2 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB MET 4275/4885AXL 3775/4885RET 2195/4885
US-20180201611-A1 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB MET 4275/4885AXL 3775/4885RET 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.